text zoom
Ongoing research continues to clarify the significance of VEGF as a key mediator of angiogenesis in prostate cancer. The fact that higher levels of VEGF have been associated with adverse outcomes in prostate cancer underscores its importance for researchers and clinicians alike.1 In studies by Delongchamps et al and Kaushal et al, VEGF has been implicated in pathologic angiogenesis associated with prostate cancer.2,3 In both localized and metastatic prostate cancer, VEGF has been shown to play a significant role.4-6 Overall, VEGF overexpression has been shown to be associated with the risk of prostate cancer progression, although further studies are needed to shed more light on the exact nature of VEGF as a prognostic factor in prostate cancer.7,8
